MCA logo
MCA logo



Roche reports positive five-year survival outcomes for extensive-stage small cell lung cancer

small cell lung cancer roche
IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with Tecentriq plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC)
IMbrella A data build on the previously reported IMpower133 trial, which was the first clinically meaningful advance in the treatment of ES-SCLC in more than twenty years

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: